BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 30201409)

  • 21. Autotaxin in liver fibrosis.
    Ikeda H; Yatomi Y
    Clin Chim Acta; 2012 Nov; 413(23-24):1817-21. PubMed ID: 22820036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lysophosphatidic acid generation by pulmonary NKT cell ENPP-2/autotaxin exacerbates hyperoxic lung injury.
    Nowak-Machen M; Lange M; Exley M; Wu S; Usheva A; Robson SC
    Purinergic Signal; 2015 Dec; 11(4):455-61. PubMed ID: 26306905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autotaxin/Lysophosphatidic Acid Axis: From Bone Biology to Bone Disorders.
    Alioli C; Demesmay L; Peyruchaud O; Machuca-Gayet I
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis.
    Tager AM
    Am J Respir Cell Mol Biol; 2012 Nov; 47(5):563-5. PubMed ID: 23125419
    [No Abstract]   [Full Text] [Related]  

  • 25. Structure-function relationships of autotaxin, a secreted lysophospholipase D.
    Hausmann J; Perrakis A; Moolenaar WH
    Adv Biol Regul; 2013 Jan; 53(1):112-7. PubMed ID: 23069371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of FOXF1 expression promotes human lung-resident mesenchymal stromal cell migration via ATX/LPA/LPA1 signaling axis.
    Cao P; Walker NM; Braeuer RR; Mazzoni-Putman S; Aoki Y; Misumi K; Wheeler DS; Vittal R; Lama VN
    Sci Rep; 2020 Dec; 10(1):21231. PubMed ID: 33277571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MAPK signaling determines lysophosphatidic acid (LPA)-induced inflammation in microglia.
    Plastira I; Bernhart E; Joshi L; Koyani CN; Strohmaier H; Reicher H; Malle E; Sattler W
    J Neuroinflammation; 2020 Apr; 17(1):127. PubMed ID: 32326963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autotaxin-LPA axis regulates hMSC migration by adherent junction disruption and cytoskeletal rearrangement via LPAR1/3-dependent PKC/GSK3β/β-catenin and PKC/Rho GTPase pathways.
    Ryu JM; Han HJ
    Stem Cells; 2015 Mar; 33(3):819-32. PubMed ID: 25376707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis.
    Bai Z; Cai L; Umemoto E; Takeda A; Tohya K; Komai Y; Veeraveedu PT; Hata E; Sugiura Y; Kubo A; Suematsu M; Hayasaka H; Okudaira S; Aoki J; Tanaka T; Albers HM; Ovaa H; Miyasaka M
    J Immunol; 2013 Mar; 190(5):2036-48. PubMed ID: 23365076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Signalling by lysophosphatidate and its health implications.
    Hemmings DG; Brindley DN
    Essays Biochem; 2020 Sep; 64(3):547-563. PubMed ID: 32451553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Function and biological activities of the autotaxin-LPA axis].
    Li ZW; Zhao YR; Zhao C; Fu R; Li ZY
    Sheng Li Xue Bao; 2011 Dec; 63(6):601-10. PubMed ID: 22193457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autotaxin-Lysophosphatidic Acid Axis Blockade Improves Inflammation by Regulating Th17 Cell Differentiation in DSS-Induced Chronic Colitis Mice.
    Dong YL; Duan XY; Liu YJ; Fan H; Xu M; Chen QY; Nan Z; Wu H; Deng SJ
    Inflammation; 2019 Oct; 42(5):1530-1541. PubMed ID: 31102124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
    Nikolaou A; Ninou I; Kokotou MG; Kaffe E; Afantitis A; Aidinis V; Kokotos G
    J Med Chem; 2018 Apr; 61(8):3697-3711. PubMed ID: 29620892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The autotaxin-lysophosphatidic acid pathway in pathogenesis of rheumatoid arthritis.
    Orosa B; García S; Conde C
    Eur J Pharmacol; 2015 Oct; 765():228-33. PubMed ID: 26297977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry.
    Cuozzo JW; Clark MA; Keefe AD; Kohlmann A; Mulvihill M; Ni H; Renzetti LM; Resnicow DI; Ruebsam F; Sigel EA; Thomson HA; Wang C; Xie Z; Zhang Y
    J Med Chem; 2020 Jul; 63(14):7840-7856. PubMed ID: 32584034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target.
    Ntatsoulis K; Karampitsakos T; Tsitoura E; Stylianaki EA; Matralis AN; Tzouvelekis A; Antoniou K; Aidinis V
    Front Immunol; 2021; 12():687397. PubMed ID: 34671341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystalline silica particles induce DNA damage in respiratory epithelium by ATX secretion and Rac1 activation.
    Wu R; Högberg J; Adner M; Stenius U; Zheng H
    Biochem Biophys Res Commun; 2021 Apr; 548():91-97. PubMed ID: 33636640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased Autotaxin Levels in Severe COVID-19, Correlating with IL-6 Levels, Endothelial Dysfunction Biomarkers, and Impaired Functions of Dendritic Cells.
    Nikitopoulou I; Fanidis D; Ntatsoulis K; Moulos P; Mpekoulis G; Evangelidou M; Vassiliou AG; Dimakopoulou V; Jahaj E; Tsipilis S; Orfanos SE; Dimopoulou I; Angelakis E; Akinosoglou K; Vassilaki N; Tzouvelekis A; Kotanidou A; Aidinis V
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 3D view of autotaxin.
    Nishimasu H; Ishitani R; Aoki J; Nureki O
    Trends Pharmacol Sci; 2012 Mar; 33(3):138-45. PubMed ID: 22277299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Expression Regulation and Biological Function of Autotaxin.
    Zhang X; Li M; Yin N; Zhang J
    Cells; 2021 Apr; 10(4):. PubMed ID: 33921676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.